MOREPEN LABORATORIES | FROM API MANUFACTURER TO GLOBAL CDMO + HEALTHCARE PLATFORM
CURRENT BUSINESS
- Morepen is traditionally known for API manufacturing, with products such as Loratadine, Montelukast, Atorvastatin and other specialised APIs.
- The business is now expanding across multiple healthcare verticals:
- APIs / Global Generics
- CDMO / Contract Manufacturing
- Domestic Formulations
- Medical Devices & Diagnostics
- Global Markets
- Longer-term optionality includes complex molecules and next-generation manufacturing opportunities.
THE TRANSFORMATION STORY
- The potential re-rating is not simply about higher API sales.
- The larger opportunity is moving up the pharmaceutical value chain.
- API business: large-scale manufacturing, exports and global customers.
- Formulations: brands, distribution and domestic healthcare.
- Medical devices: installed base, consumables and recurring demand.
- If successfully executed, Morepen could evolve from an API manufacturer into a diversified pharmaceutical and healthcare platform.
CDMO — THE NEXT MAJOR GROWTH ENGINE
- FY27 could become an inflection year for the CDMO business.
- Secured a ₹825 Cr multi-year CDMO mandate from a global pharma major.
- ₹58 Cr of commercial dispatches already completed in Q1 FY27.
- Management guides for ~₹225 Cr supplies in Q2 FY27.
- CDMO could contribute 50%+ of total revenue by Q3–Q4 FY27.
- The program could potentially add ~50–60% to the existing core API business.
WHY CDMO MATTERS
- Moves the company from selling individual APIs toward higher-value contract manufacturing.
- Large pharma relationships can create recurring commercial volumes after successful validation.
- Revenue progression should follow:
- Customer onboarding
- Product validation
- Commercial manufacturing
- Scale-up
- The key question is now execution speed rather than order-book availability.
WHAT TO WATCH
- Conversion of the ₹825 Cr mandate into actual recurring revenue.
- Q2 supplies versus the ~₹225 Cr management target.
- CDMO contribution reaching 50%+ of revenue.
- Ability to scale manufacturing without significant margin dilution.
- Further customer additions and movement toward complex molecules.
KEY TAKEAWAY
Morepen's CDMO ramp could shift the company from an API-led business toward a higher-value global pharma platform.
Stock Stats | Stock info | Infographics
@Stockinfo333
1September 4, 2026 1.9K 12
